Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Gefapixant can become a 'game changer' in treating people with persistent cough, reveals study

10/10/2022

0 Comments

 
Gefapixant can become a game changer in treating people with persistent cough reveals study.
A new drug Gefapixant 45 mg twice per day is the first treatment to show efficacy with an acceptable safety profile in phase 3 clinical trials for refractory chronic cough or unexplained chronic cough, revealed a study paper published in The Lancet.
 
If Gefapixant becomes available in the market, it is expected to become a ‘game changer’  in the field of respiratory medicine, by treating thousands of people suffering from severe or persistent cough.
 
A persistent cough is a cough that lasts for more than eight weeks. Chronic cough is responsible for a decrease in quality of life. Chronic cough affects approximately 5–10% of the global population. In UK itself, 4 to 12% of people suffer from it as per published reports.
 
Many patients with refractory chronic cough or unexplained chronic cough have a long-term disease with substantial deterioration in their quality of life.
 
Currently, there are no approved therapies for refractory chronic cough or unexplained chronic cough, and clinicians often rely on off-label treatments such as morphine, amitriptyline, gabapentin, pregabalin, and speech therapy. Thus, an unmet need remains for safe and effective medications for chronic cough.

The discovery of a new class of drugs—P2X3 receptor antagonists appear to be effective hope to this debilitating problem.

Gefapixant is an oral P2X3 receptor antagonist . As per the news report, a global trial conducted in 17 to 20 countries, involving nearly 2000 individuals found that the Gefapixant reduces chronic coughing in nearly 60 to 70 percent of people.
 
The news report also stated- the study indicated that some of the patients found that their taste ability was either affected or disappeared when they were consuming the drug. However, they later believed that the side effects are worth paying for as they are now relieved from coughing and not just that, they are now able to sleep better than they used to when they were coughing. 

Here’s the link to the study papers https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02348-5/fulltext and  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02438-7/fulltext

Disclaimer: The content of this blog is for educational purpose only and not medical advice. Consult a registered medical doctor before taking any medicine.

​Follow Shruti on Twitter, Facebook, YouTube, LinkedIn

Categories:  Life Sciences | Mistake-Proofing

Keywords and Tags:
#coughmedicine #gefapixant #Lancetstudy
Get In Touch
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media